表紙
市場調査レポート

MediPoint:大動脈ステントグラフト - 世界市場の分析と予測

MediPoint: Aortic Stent Grafts - Global Analysis and Market Forecasts

発行 GlobalData 商品コード 316749
出版日 ページ情報 英文 260 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
MediPoint:大動脈ステントグラフト - 世界市場の分析と予測 MediPoint: Aortic Stent Grafts - Global Analysis and Market Forecasts
出版日: 2014年10月15日 ページ情報: 英文 260 Pages
概要

大動脈ステントグラフトは、動脈瘤として知られる動脈の弱い部位を補強するために、最もよく使用されます。ステントグラフトは、患者の動脈に留置し、動脈瘤の上下にしっかり封をするように設計されています。腹部大動脈瘤だけでなく胸部大動脈瘤の治療にも使用されています。

当レポートでは、世界の大動脈ステントグラフト装置市場について調査分析し、産業の概要、アンメットニーズ、市場機会、市場促進要因、競合評価、パイプライン製品について検証するほか、主要企業プロファイルなどについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 産業の概要

  • 概要
  • 適応症
  • 臨床転帰
  • 処置の動向
  • 市場参入
  • 規制問題/リコール
  • 合併、取引、買収
  • 経済的影響

第4章 アンメットニーズ

  • 合併症に対処
  • シールゾーンとランディングゾーン
  • ショートネック
  • 費用の抑制
  • 目立たないシステム
  • 専用の有窓ステントグラフト
  • 分岐型ステントグラフト
  • 胸部血管内動脈瘤修復:アンメットニーズ
  • 長期的な臨床データ

第5章 市場機会分析

  • 新興市場
  • 胸部大動脈疾患市場
  • 医師の訓練プログラムの追加
  • 革新的な技術
  • 低侵襲の動向

第6章 市場促進要因、障壁、代替

  • 促進要因
  • 障壁
  • 代替

第7章 競合評価

  • 概要
  • 主な上市製品

第8章 パイプライン評価

  • 概要
  • 製品プロファイル

第9章 注目すべき臨床試験

第10章 現在/将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Cook Medical
    • Endologix
    • Gore Medical
    • Medtronic
    • Terumo Corporation
    • Altura Medical
    • Aptus Endosystems
    • Bolton Medical
    • Braile Biomedica
    • B. Braun
    • Cardiatis
    • LeMaitre Vascular
    • Lifetech Scientific
    • Getinge Group
    • Grikin Advanced Materials
    • Johnson & Johnson's Cordis Corporation
    • Jotec
    • Lombard Medical
    • MicroPort Scientific Corporation
    • Nano Endoluminal
    • TriVascular
    • Weike Medical Apparatus and Instrument
    • YTH Biological Material Scitech

第11章 市場の見通し

  • 企業の市場シェア
  • 市場セグメント別
  • 地域別

第12章 付録

図表

目次
Product Code: GDME0186MAR

Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. Since their introduction in patients in 1991, aortic stent graft devices have gained wide acceptance and availability, with their adoption fueled in great part by advances in stent-graft design and by a variety of devices for various anatomic features. Over time, these devices have gained traction for use in patients with ruptured aneurysms because they are minimally invasive and have shorter recovery times.

This report focuses on the aortic stent graft implant market for abdominal and thoracic aneurysms. The abdominal aortic market comprises about 80-90% of the market, with the niche market being the thoracic one. The thoracic aneurysm repair market is still a young market where there is a strong pipeline of products from both the large manufacturers and small emerging players. For most manufacturers, following the successful launch of an AAA product, the thoracic stent graft segment presents the opportunity with the most unmet needs for pursuit.

The 10MM are covered and forecast in this report, which provides the unmet needs, future adoption, and Compound Annual Growth Rates (CAGRs) in both the abdominal stent graft and thoracic stent graft markets. GlobalData's analysis demonstrates this market to be a young and growing market, subject to rapid technological development and with much room for product adoption. The global aortic stent grafts market is determined for the 10 countries with insight into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis. The report identifies the unmet needs in the market while providing an understanding of physicians' perceptions and decision-making processes in using and evaluating the adoption of the stent graft.

Highlights

Key Questions Answered

  • (Q). What is the current and future aortic stent market outlook in the developed and emerging markets (Q). What trends are affecting the global stent graft market fro both AAA and TAA
  • (Q). Which are the key, high growth markets that stent manufacturers should expand into (Q). Who are the up and coming new players in the stent graft market
  • The traditional open surgery approach has been used for decades. (Q). What are the drivers moving physicians to take the endovascular approach instead (Q). What are the unmet needs for current generation products
  • (Q). What clinical factors and technical specifications influence a physician to use one type of stent graft over another (Q). What is physician perception and market outlook of endovascular repair
  • (Q). What are the challenges and complications of stent grafts that have hindered widespread adoption
  • (Q). With developing the next-generation of aortic stent grafts and what are the disruptive technologies and game changing trends that manufacturers are focusing on

Reasons to buy

  • "What Physicians Think" quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading Vascular Surgeons from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Industry Overview

  • 3.1. Overview
  • 3.2. Indications
    • 3.2.1. Aortic Abdominal Aneurysm
    • 3.2.2. Thoracic Aortic Aneurysm
    • 3.2.3. Aortic Dissection
  • 3.3. Clinical Outcomes
    • 3.3.1. Lifestyle Changes
    • 3.3.2. Medication
    • 3.3.3. Open Surgery
    • 3.3.4. Endovascular Repair
  • 3.4. Procedure Trends
    • 3.4.1. Global
    • 3.4.2. US
    • 3.4.3. EU
    • 3.4.4. Asia-Pacific
    • 3.4.5. South America
  • 3.5. Market Access
    • 3.5.1. Adoption
    • 3.5.2. Regulation
    • 3.5.3. Reimbursement
  • 3.6. Regulatory Issues/Recalls
    • 3.6.1. Anaconda Back on the Market in March 2014 after a Voluntary Recall of Anaconda by Vascutek
    • 3.6.2. Terminated FDA's Class II Recall of TriVascular's Ovation Prime in April 2014
  • 3.7. Mergers, Deals, and Acquisitions
    • 3.7.1. Medtronic Acquires Covidien
    • 3.7.2. TriVascular Launches $100m Initial Public Offering
    • 3.7.3. Lombard Medical Pursues US Initial Public Offering
    • 3.7.4. TriVascular Raises $40m in Series E Financing
    • 3.7.5. LifeTech Scientific Creates Partnership with Medtronic
    • 3.7.6. LeMaitre Vascular Terminates Distribution Agreement with Endologix
    • 3.7.7. Jotec Enters Licensing Agreement with Hydromer
    • 3.7.8. Endologix Public Offering of Notes
    • 3.7.9. Aptus Endosystems Secures Financing
    • 3.7.10. Altura Medical Secures Financing
    • 3.7.11. Endologix Acquires Nellix Endovascular
  • 3.8. Economic Impact
    • 3.8.1. Economic Impact of Aneurysms
    • 3.8.2. Treatment Costs of Aortic Aneurysms

4. Unmet Needs

  • 4.1. Addressing the Complications
    • 4.1.1. Endoleaks
    • 4.1.2. Ischemic Complications
    • 4.1.3. Limb Thrombosis
    • 4.1.4. Infection
    • 4.1.5. Paraplegia in Thoracic Aortic Aneurysm
  • 4.2. The Seal and Landing Zone
  • 4.3. Short Neck
  • 4.4. Cost Containment
  • 4.5. More Low Profile Systems
  • 4.6. Customized Fenestrated Stent Grafts
  • 4.7. Multi-Branch Stent Grafts
  • 4.8. Thoracic Endovascular Aneurysm Repair Unmet Needs
  • 4.9. Long-Term Clinical Data

5. Market Opportunity Analysis

  • 5.1. Emerging Markets
  • 5.2. Thoracic Aortic Disease Market
  • 5.3. Addition of Physician Training Programs
  • 5.4. Disruptive Technologies
  • 5.5. Minimally Invasive Trend

6. Market Drivers, Barriers, and Substitutes

  • 6.1. Driver: Rising Disease Prevalence
    • 6.1.1. Diabetes Mellitus
    • 6.1.2. Hypertension
    • 6.1.3. Obesity
    • 6.1.4. Tobacco Use
  • 6.2. Driver: Aging
  • 6.3. Driver: Imaging
  • 6.4. Driver: Improved Clinical Outcomes with Endovascular Therapy
  • 6.5. Driver: Time Savings
  • 6.6. Driver: Patient Demand and Awareness
  • 6.7. Driver: Technological Developments
    • 6.7.1. Custom Branched and Fenestrated Stent Grafts
    • 6.7.2. Low Profile Delivery Systems
  • 6.8. Driver: Rising Competition and Innovation
  • 6.9. Barrier: Availability of Venture Capital
  • 6.10. Barrier: Burden of Rising Regulation
  • 6.11. Barrier: High Treatment Cost
  • 6.12. Barrier: Proving Long-Term Efficacy
  • 6.13. Barrier: High Radiation Dosages with Excessive Imaging
  • 6.14. Surgical Limitations
  • 6.15. Barrier: Medical Device Excise Tax
  • 6.16. Substitute: Open Surgery
  • 6.17. Substitute: Chimney Technique versus Fenestrated Grafts

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Key Marketed Products
    • 7.2.1. Endovascular Aneurysm Repair and Thoracic Endovascular Aneurysm Repair Products

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Product Profiles
    • 8.2.1. Altura Medical Endograft
    • 8.2.2. Cordis INCRAFT
    • 8.2.3. EndoSpan Horizon
    • 8.2.4. EndoSpan Nexus
    • 8.2.5. MicroPort Scientific Castor Branched Stent Graft System
    • 8.2.6. BiFlow Medical Novel Side-Branch Stent
    • 8.2.7. Endoluminal Sciences Endograft Mechanism
    • 8.2.8. Medtronic Valiant Mona LSA Stent Graft System
    • 8.2.9. Endologix Ventana Fenestrated Stent Graft

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Altura Medical
  • 9.3. Cook Medical
  • 9.4. Gore Medical
  • 9.5. Terumo Corporation
  • 9.6. Endologix
  • 9.7. TriVascular
  • 9.8. Bolton Medical
  • 9.9. Medtronic
  • 9.10. Cordis Corporation

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. Cook Medical
    • 10.3.2. Endologix
    • 10.3.3. Gore Medical
    • 10.3.4. Medtronic
    • 10.3.5. Terumo Corporation
    • 10.3.6. Altura Medical
    • 10.3.7. Aptus Endosystems
    • 10.3.8. Bolton Medical
    • 10.3.9. Braile Biomedica
    • 10.3.10. B. Braun
    • 10.3.11. Cardiatis
    • 10.3.12. LeMaitre Vascular
    • 10.3.13. Lifetech Scientific
    • 10.3.14. Getinge Group
    • 10.3.15. Grikin Advanced Materials
    • 10.3.16. Johnson & Johnson's Cordis Corporation
    • 10.3.17. Jotec
    • 10.3.18. Lombard Medical
    • 10.3.19. MicroPort Scientific Corporation
    • 10.3.20. Nano Endoluminal
    • 10.3.21. TriVascular
    • 10.3.22. Weike Medical Apparatus and Instrument
    • 10.3.23. YTH Biological Material Scitech

11. Market Outlook

  • 11.1. Company Market Share
    • 11.1.1. Global Market Share
    • 11.1.2. US Market Share
    • 11.1.3. EU Market Share
  • 11.2. By Market Segment
    • 11.2.1. Overview
    • 11.2.2. Endovascular Aneurysm Repair
    • 11.2.3. Thoracic Endovascular Aneurysm Repair
  • 11.3. By Geography
    • 11.3.1. Global Overview
    • 11.3.2. US
    • 11.3.3. EU
    • 11.3.4. Asia-Pacific
    • 11.3.5. South America

12. Appendix

  • 12.1. Bibliography
  • 12.2. Abbreviations
  • 12.3. Research Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in this Study
    • 12.4.1. Christopher Abularrage, MD, FACS
    • 12.4.2. Gaspar Mestres Alomar, MD
    • 12.4.3. Enio Buffolo, MD, PhD
    • 12.4.4. Ludovic Canaud, MD, PhD
    • 12.4.5. Holger Eggebrecht, MD
    • 12.4.6. Daisuke Fukui, MD, PhD
    • 12.4.7. Germano Melissano, MD
    • 12.4.8. Dr. Raghuram Sekhar MS, FRCS (Edinburgh), FRCS (Glasgow)
    • 12.4.9. Ferdinand Serracino-Inglott, MD, MSc, FRCSI, FRCS (Gen Surg), DIC
    • 12.4.10. Jiang Xiong, MD, PhD
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Primary Research - Physician and Industry Interviews
    • 12.5.3. Expert Panel Validation
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Analysts
    • 12.7.2. Global Head of Healthcare
  • 12.8. About MediPoint
  • 12.9. About GlobalData
  • 12.10. Disclaimer

List of Tables

  • Table 1: Summary of Indications, Symptoms, and Treatments
  • Table 2: Thoracic Aortic Aneurysm Types
  • Table 3: Medications for Reducing Risk of Aneurysm Growth and Rupture
  • Table 4: Advantages and Disadvantages of Open Repair versus Endovascular Repair
  • Table 5: Global Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Table 6: Global Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Table 7: Group Purchasing Organizations in the US and EU
  • Table 8: Regulatory Differences between the US and EU
  • Table 9: Medicare National Average of Inpatient Hospital Payment for EVAR and TEVAR, 2013-2014
  • Table 10: Medicare Coding Guide for EVAR and TEVAR, 2014
  • Table 11: Direct and Indirect Costs of Open Surgery and Endovascular Repair
  • Table 12: Comparison Costs and Other Variables for Treating AAA By Open Repair and Stent Grafts in 2012 ($US)
  • Table 13: Endoleak Types
  • Table 14: Zenith Family Marketed Products
  • Table 15: Zenith AAA SWOT
  • Table 16: Zenith TAA SWOT
  • Table 17: Endologix's Marketed Products
  • Table 18: AFX Endovascular SWOT
  • Table 19: IntuiTrak Powerlink System SWOT
  • Table 20: Gore Medical's Marketed Products
  • Table 21: Gore AAA Product SWOT
  • Table 22: Gore TAA Product SWOT
  • Table 23: Medtronic's Marketed Products
  • Table 24: Medtronic AAA Product SWOT
  • Table 25: Medtronic TAA Product SWOT
  • Table 26: Terumo Corporation Marketed Products
  • Table 27: Terumo Corporation AAA Product SWOT
  • Table 28: SWOT Analysis - Altura Medical Endograft
  • Table 29: SWOT Analysis - Cordis INCRAFT
  • Table 30: SWOT Analysis - EndoSpan Horizon
  • Table 31: SWOT Analysis - EndoSpan Nexus
  • Table 32: SWOT Analysis - MicroPort Scientific Castor Branched Stent Graft System
  • Table 33: SWOT Analysis - BiFlow Medical Novel Side-Branch Stent
  • Table 34: SWOT Analysis - Endoluminal Sciences Endograft Mechanism
  • Table 35: SWOT Analysis - Medtronic Valiant Mona LSA Stent Graft
  • Table 36: SWOT Analysis - Endologix Ventana Fenestrated Stent Graft
  • Table 37: Major Clinical Trials of Altura Medical's Aortic Stent Grafts
  • Table 38: Major Clinical Trials of Cook Medical's Aortic Stent Grafts
  • Table 39: Major Clinical Trials of Gore Medical's Aortic Stent Grafts
  • Table 40: Major Clinical Trials of Terumo's Aortic Stent Grafts
  • Table 41: Major Clinical Trials of Endologix's Aortic Stent Grafts
  • Table 42: Major Clinical Trials of TriVascular's Aortic Stent Grafts
  • Table 43: Major Clinical Trials of Bolton Medical's Aortic Stent Grafts
  • Table 44: Major Clinical Trials of Medtronic's Aortic Stent Grafts
  • Table 45: Major Clinical Trials of Cordis' Aortic Stent Grafts
  • Table 46: Company Profile - Cook Medical
  • Table 47: Cook Medical Marketed Products
  • Table 48: SWOT Analysis - Cook Medical
  • Table 49: Company Profile - Endologix Inc.
  • Table 50: Endologix Marketed Products
  • Table 51: Endologix Pipeline Products
  • Table 52: SWOT Analysis - Endologix Inc.
  • Table 53: Company Profile - Gore Medical
  • Table 54: Gore Medical Marketed Products
  • Table 55: SWOT Analysis - Gore Medical
  • Table 56: Company Profile - Medtronic
  • Table 57: Medtronic Marketed Products
  • Table 58: SWOT Analysis - Medtronic
  • Table 59: Company Profile - Terumo Corporation
  • Table 60:Terumo Corporation Marketed Products
  • Table 61: SWOT Analysis - Terumo Corporation
  • Table 62: Company Profile - Altura Medical Inc.
  • Table 63: Altura Medical Inc. Marketed Products
  • Table 64: SWOT Analysis - Altura Medical Inc.
  • Table 65: Company Profile - Aptus Endosystems, Inc.
  • Table 66: Aptus Endosystems Inc. Marketed Products
  • Table 67: SWOT Analysis - Aptus Endosystems Inc.
  • Table 68: Company Profile - Bolton Medical
  • Table 69: Bolton Medical Marketed Products
  • Table 70: SWOT Analysis - Bolton Medical
  • Table 71: Company Profile - Braile Biomedica
  • Table 72: Braile Biomedica Marketed Products
  • Table 73: SWOT Analysis - Braile Biomedica
  • Table 74: Company Profile - B. Braun
  • Table 75: B. Braun Marketed Products
  • Table 76: SWOT Analysis - B. Braun
  • Table 77: Company Profile - Cardiatis
  • Table 78: Cardiatis Marketed Products
  • Table 79: SWOT Analysis - Cardiatis
  • Table 80: Company Profile - LeMaitre Vascular
  • Table 81: LeMaitre Vascular Medical Marketed Products
  • Table 82: SWOT Analysis - LeMaitre Vascular
  • Table 83: Company Profile - Lifetech Scientific
  • Table 84: Lifetech Scientific Marketed Products
  • Table 85: SWOT Analysis - Lifetech Scientific
  • Table 86: Company Profile - Getinge Group
  • Table 87: Getinge Group Marketed Products
  • Table 88: SWOT Analysis - Getinge Group
  • Table 89: Company Profile - Grikin Advanced Materials
  • Table 90: Grikin Advanced Materials Marketed Products
  • Table 91: SWOT Analysis - Grikin Advanced Materials
  • Table 92: Company Profile - Johnson & Johnson Cordis Corporation
  • Table 93: Cordis Corporation's Pipeline Product
  • Table 94: SWOT Analysis - Cordis Corporation
  • Table 95: Company Profile - Jotec
  • Table 96: Jotec's Marketed Products
  • Table 97: SWOT Analysis - Jotec
  • Table 98: Company Profile - Lombard Medical
  • Table 99: Lombard Medical Marketed Products
  • Table 100: SWOT Analysis - Lombard Medical
  • Table 101: Company Profile - Microport Scientific Corporation
  • Table 102: MicroPort Scientific Marketed Products
  • Table 103: SWOT Analysis - MicroPort Scientific
  • Table 104: Company Profile - Nano Endoluminal
  • Table 105: Nano Endoluminal Medical Marketed Products
  • Table 106: SWOT Analysis - Nano Endoluminal
  • Table 107: Company Profile - TriVascular
  • Table 108: TriVascular Marketed Products
  • Table 109: SWOT Analysis - TriVascular
  • Table 110: Global Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011-2020
  • Table 111: Global Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Table 112: Global Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Table 113: Aortic Stent Grafts Sales ($m) for the Major Markets, 2011-2020
  • Table 114: Aortic Stent Grafts Sales ($m) for the US, 2011-2020
  • Table 115: Aortic Stent Grafts Sales ($m) Forecast for the 5EU, 2011-2020
  • Table 116: Aortic Stent Grafts Sales ($m) Forecast for France, 2011-2020
  • Table 117: Aortic Stent Grafts Sales ($m) Forecast for Germany, 2011-2020
  • Table 118: Aortic Stent Grafts Sales ($m) Forecast for Italy, 2011-2020
  • Table 119: Aortic Stent Grafts ($m) Forecast for Spain, 2011-2020
  • Table 120: Aortic Stent Grafts Sales ($m) Forecast for the UK, 2011-2020
  • Table 121: Aortic Stent Grafts Sales ($m) Forecast for the APAC Region, 2011-2020
  • Table 122: Aortic Stent Grafts Sales ($m) Forecast for Japan, 2011-2020
  • Table 123: Aortic Stent Grafts Sales ($m) Forecast for China, 2011-2020
  • Table 124: Aortic Stent Grafts Sales ($m) Forecast for India, 2011-2020
  • Table 125: Aortic Stent Grafts Sales ($m) Forecast for Brazil, 2011-2020

List of Figures

  • Figure 1: Treatment Methodology Markov Model
  • Figure 2: Aortic Stent Graft Product Image
  • Figure 3: Global Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 4: Global Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 5: US Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 6: US Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 7: EU Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 8: EU Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 9: APAC Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 10: APAC Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 11: South America Abdominal Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 12: South America Thoracic Aortic Stent Grafts Procedure Volume, 2011-2020
  • Figure 13: Global Market Share for EVAR, 2013
  • Figure 14: Global Market Share for TEVAR, 2013
  • Figure 15: US Market Share for EVAR, 2013
  • Figure 16: US Market Share for TEVAR, 2013
  • Figure 17: EU Market Share for EVAR, 2013
  • Figure 18: EU Market Share for TEVAR, 2013
  • Figure 19: Global Aortic Stent Grafts Sales ($m) Forecast, by Segment, 2011-2020
  • Figure 20: Global Aortic Stent Grafts Sales ($m) Forecast, EVAR, 2011-2020
  • Figure 21: Global Aortic Stent Grafts Sales ($m) Forecast, TEVAR, 2011-2020
  • Figure 22: Aortic Stent Grafts Sales ($m) for the Major Markets, 2011-2020
  • Figure 23: Aortic Stent Grafts by Major Market, 2013 and 2020
  • Figure 24: US Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 25: 5EU Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 26: France Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 27: Germany Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 28: Italy Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 29: Spain Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 30: UK Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 31: APAC Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 32: Japan Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 33: China Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 34: India Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 35: Brazil Sales ($m) Forecast for Aortic Stent Grafts, 2011-2020
  • Figure 36: Aortic Stent Graft Primary Research, Supply and Demand-Side Interviews
Back to Top